arrow Log In to View Account     |          
UTASIP
UTASIP Logo
 


Sponsored by The University of Tennessee College of Pharmacy
This activity is supported by an educational grant from Bristol-Myers Squibb Company.

OVERVIEW
Lung cancer is the leading cause of cancer-related mortality in the United States, accounting for more than 200 000 new cancer cases and more than 150 000 cancer-related deaths each year. Non–small-cell lung cancer (NSCLC) accounts for more than 85% of lung cancer cases, and is usually associated with a poor prognosis. Health-system pharmacists play a significant role in the treatment of NSCLC by providing valuable information for clinicians and patients throughout the course of therapy, including appropriate drug selection, dosing, and side-effect counseling and management. This University of Tennessee Advanced Studies in Pharmacy activity, which is based on a symposium held at the 46th ASHP Mid-Year Clinical Meeting & Exhibition on December 7, 2011, in New Orleans, LA, will provide pharmacists’ perspectives on the use of targeted agents in NSCLC, including the efficacy and safety of combining these agents with one another and with other treatment approaches for patients with advanced disease. This information is meant to improve participants’ ability to use evidence-based methods to optimize the care of patients with NSCLC, by incorporating patient-specific and tumor-specific factors and histologic markers and help them develop strategies to prevent and manage treatment-related adverse events.

GOAL
By providing the most up-to-date information, health-system pharmacists will gain a better understanding of patient-specific factors, emerging molecularly targeted therapies, and the role of combination therapy in the management of NSCLC, leading to improved patient outcomes.

TARGET AUDIENCE
This activity is designed for health-system pharmacists. No prerequisites required.

LEARNING OBJECTIVES
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. At the conclusion of this activity, the participant should be able to:

  • FORMULATE methods for optimizing care of patients with NSCLC by focusing on patient- and tumor-specific factors and histologic markers.
  • ASSESS clinical data that suggest a role for molecularly targeted therapies in treatment of patients with advanced NSCLC.
  • EXPLAIN how inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor pathways can improve patient outcomes.
  • EVALUATE the role of combination therapy for the management of advanced NSCLC.
  • DETERMINE strategies for optimizing care of patients with NSCLC by focusing on proper dosing, adverse effects, prevention/management, and identification of drug-drug interactions.

ACCREDITATION STATEMENT
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.

CREDIT DESIGNATION STATEMENT
acpe logoThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based program will provide a statement for 1.25 contact hour credit (0.125 CEU) and will be available at the completion of the activity. Successful completion includes participating in the activity, completing a self-assessment instrument with a score of at least 70%, and completing an evaluation instrument. If you score less than 70% on the self-assessment instrument, you will be allowed to complete the examination 2 more times. A statement of participation will be available online immediately following successful completion of the activity. ACPE Program # 0064-0000-12-201-H01-P. Beginning 2012 your CE credits will also be submitted electronically to NABP. Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website (www.nabp.net/programs/cpe-monitor/cpe-monitor-service) or contact NABP Customer Service: custserv@nabp.net or telephone 847-391-4406.

The estimated time to complete this activity: 1.25 hour.

Release date: April 30, 2012. Expiration date: April 30, 2013.

FULL DISCLOSURE POLICY AFFECTING CPE ACTIVITIES
As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

J. Aubrey Waddell, PharmD, BCOP (Chair)
Oncology Clinical Pharmacist
Blount Memorial Hospital
Professor
University of Tennessee College of Pharmacy
Memphis, Tennessee
Dr Waddell reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

Val R. Adams, PharmD, FCCP, BCOP
Associate Professor
University of Kentucky
Lexington, Kentucky
Dr Adams reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

R. Donald Harvey, PharmD, FCCP, BCPS, BCOP
Assistant Professor of Hematology/Medical Oncology
Director, Phase 1 Clinical Trials Section
Winship Cancer Institute of Emory University
Atlanta, Georgia
Dr Harvey reports receiving research funding from Bristol-Myers Squibb Company, Lilly USA, LLC, Sanofi-Aventis, and Synta Pharmaceuticals Corporation.

OFF-LABEL PRODUCT DISCUSSION
In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the reader of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.

DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

GRIEVANCE POLICY
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at gfarr@utasip.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

FEE INFORMATION
There is no fee for this educational activity.

TABLE OF CONTENTS
Pre-Test

Expanding the Treatment Armamentarium for Non–Small-Cell Lung Cancer: Pharmacist Perspectives

J. Aubrey Waddell, PharmD, BCOP

NSCLC: Background and Clinical Practice Guidelines
Val R. Adams, PharmD, FCCP, BCOP

Current and Emerging Therapies for Advanced NSCLC
R. Donald Harvey, PharmD, FCCP, BCPS, BCOP

Pharmacy-Related Concerns: Optimizing Care for Patients with NSCLC
Val R. Adams, PharmD, FCCP, BCOP

Post-Test

procced to pretest
University of Tennessee Advanced Studies in Pharmacy (ISSN-1558-0350), is published by Galen Publishing, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2015 by Galen Publishing. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of The Healthcare Media Group, LLC.